| Di bukaata | anti-diabetic medication  |
|---|---|
| Trading name | Mounjaro |
| Taba laɣim di fiila | Glucagon like peptide 1 receptor,Gastric inhibitory polypeptide receptor |
| Described at URL | https://www.wired.com/story/new-drug-switched-off-appetite-mounjaro/ |
| Bachikpani mali tuma | anti-diabetic medication |
| NCI Thesaurus ID | C174817 |
Tirzepatide, nyɛla tim ka bɛ kɔhirili ni yuli din nyɛMounjaro miniZepbound, di nyɛla ti'shɛli bɛ ni mali tibiri "type 2 diabetes" mini "obesity".[1][2] Di tooi vandimi ni bindirigu mini ningbuna dahimbu.[1] Ka bɛ chibirili niŋdi ningbuna ni bakoi yini kam zuɣu.[1]
Di barinanima shɛŋa n-nyɛ "nausea", tiri ka nyera, pufahili, ni puuni berim.[1] Di barina shɛŋa ni tooi lahi nyɛ"pancreatitis, low blood sugar, allergic reactions, ni gallbladder disease".[1] Paɣa yi mali puli ka voli li di nyɛla din ni tooi dam bia maa.[1] Di nyɛla din deeri glucagon-like peptide-1 (GLP-1) mini glucose-dependent insulinotropic polypeptide (GIP) ka pahiri "insulin" zaŋ chaŋ bindirigu polo.[1][3]
Tirzepatide zaŋ tibi tuuli saɣiti daa nyɛla United States, Europe, ni United Kingdom yuuni 2022.[1][3][4] United States tingbani ni di liɣiri nyɛla 1,000 USD zaŋ chaŋ bakoi dibaa anahi yuuni 2022.[5]